Implementing Novel Value Elements and Methods in Health Technology Assessment: The Case of Advanced Therapies

Speaker(s)

Moderator: William Vincent Padula, PhD, MSc, MS, Department of Pharmaceutical and Health Economics, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical and Health Economics, University of Southern California, Los Angeles, CA, USA
Speakers: Allan Wailoo, MA, MSc, PhD, School of Health and Related Research, University of Sheffield, SHEFFIELD, UK; Marharyta Khmelovska, M.Ec., State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine; Melanie D. Whittington, PhD, MS, Valusphere, Boston, MA, USA

  • Objectives: Discuss whether conventional cost-utility analysis will continue to serve a meaningful purpose for the health technology assessment (HTA) of advanced therapies, or if novel value elements and methods will become the next evolution for the HTA of advanced therapies.
  • Background: Conventional cost-utility analysis has been criticized for omitting many important elements of value, such as value of hope, loss of exclusivity, insurance value, real option value, equity, and severity. These novel elements of value may have particular relevance for the comprehensive value assessment of advanced therapies. Despite these value elements being omitted, conventional cost-utility analysis remains standard practice across many HTA bodies. Novel methodological advances such as generalized risk-adjusted cost-effectiveness (GRACE), distributional cost-effectiveness analysis (DCEA), and stacked cohort models for dynamic pricing may offer options to incorporate these additional elements of value quantitatively. At present, these methods are not traditionally implemented within HTA.
  • Panel: Dr. Padula will introduce novel value elements (e.g., petals of the ISPOR value flower) and novel value methods (e.g., GRACE, DCEA, stacked cohort models) with an emphasis on their relevance for advanced therapies. Then the members of the panel representing England (Prof. Wailoo), Central/Eastern Europe (Ms. Khmelovska), and North America (Dr. Whittington) will first discuss how advanced therapies are traditionally assessed in their country followed by a debate on whether these elements and methods are currently feasible and ethical for implementation within the HTA for advanced therapies.

Code

239

Topic

Health Technology Assessment